Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Explore (New York, N.Y.)|January 26, 2020
Introducing integrative primary health care to an interprofessional audience: Feasibility and impact of an asynchronous online courseAudrey J Brooks, Mei-Kuang Chen, Elizabeth Goldblatt, et al.
American Journal of Cancer Research|February 10, 2022
Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancerDavid J H Shih, Mei-Kuang Chen, Jun Yin, et al.
Materials (Basel, Switzerland)|August 30, 2020
Glow Discharge Plasma Treatment on Zirconia Surface to Enhance Osteoblastic-Like Cell Differentiation and Antimicrobial EffectsYu-Hwa Pan, Jerry Chin Yi Lin, Mei Kuang Chen, et al.
Explore (New York, N.Y.)|April 2, 2020
Professional development in integrative health through an interprofessional online course in clinical settingsAudrey J Brooks, Victoria Maizes, John Billimek, et al.
American Journal of Cancer Research|March 21, 2020
Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinomaXian Sun, Chia-Wei Li, Wei-Jan Wang, et al.
American Journal of Cancer Research|April 6, 2019
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cellsYe Han, Mei-Kuang Chen, Hung-Ling Wang, et al.
American Journal of Cancer Research|April 13, 2017
A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinomaChun-Te Chen, Yi-Chun Chen, Yi Du, et al.
Cancer Research|August 26, 2024
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast CancerMi Li, Amriti R Lulla, Yan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionShiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
Nature Communications|January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 inductionLinjie Luo, Yan Wang, Tuyen Bui, et al.
Pageof 5